HighTower Advisors LLC Increases Stock Position in Global X Genomics & Biotechnology ETF $GNOM

HighTower Advisors LLC increased its position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 16.7% in the first quarter, Holdings Channel.com reports. The fund owned 15,242 shares of the company’s stock after purchasing an additional 2,184 shares during the period. HighTower Advisors LLC’s holdings in Global X Genomics & Biotechnology ETF were worth $121,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in GNOM. Stifel Financial Corp raised its holdings in shares of Global X Genomics & Biotechnology ETF by 38.8% during the fourth quarter. Stifel Financial Corp now owns 14,690 shares of the company’s stock valued at $143,000 after purchasing an additional 4,110 shares during the last quarter. Jane Street Group LLC raised its holdings in shares of Global X Genomics & Biotechnology ETF by 4.9% during the fourth quarter. Jane Street Group LLC now owns 133,405 shares of the company’s stock valued at $1,295,000 after purchasing an additional 6,221 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Global X Genomics & Biotechnology ETF during the fourth quarter valued at approximately $148,000. Strive Asset Management LLC purchased a new position in shares of Global X Genomics & Biotechnology ETF during the fourth quarter valued at approximately $409,000. Finally, Two Sigma Investments LP raised its holdings in shares of Global X Genomics & Biotechnology ETF by 74.5% during the fourth quarter. Two Sigma Investments LP now owns 85,500 shares of the company’s stock valued at $830,000 after purchasing an additional 36,500 shares during the last quarter. 56.95% of the stock is owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Stock Up 2.5%

GNOM opened at $37.99 on Friday. The firm has a 50 day moving average price of $35.74 and a 200-day moving average price of $33.88. Global X Genomics & Biotechnology ETF has a twelve month low of $27.20 and a twelve month high of $46.72. The stock has a market capitalization of $190.71 million, a price-to-earnings ratio of -16.24 and a beta of 1.03.

Global X Genomics & Biotechnology ETF Dividend Announcement

The business also recently disclosed a dividend, which was paid on Monday, July 7th. Stockholders of record on Friday, June 27th were issued a dividend of $0.0331 per share. The ex-dividend date of this dividend was Friday, June 27th.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.